Freenome Inc(FRNM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.07 | Insider Own | 29.11% | Shs Outstand | 107.5M | Perf Week | 6.63% |
| Market Cap | 1.41B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 76.2M | Perf Month | -16.56% |
| Enterprise Value | 1.41B | PEG | - | EPS next Q | 0.14 | Inst Own | 33.17% | Short Float | 4.46% | Perf Quarter | 16.55% |
| Income | -0.00B | P/S | - | EPS this Y | - | Inst Trans | 9.5% | Short Ratio | 3.92 | Perf Half Y | 15.93% |
| Sales | 0.00B | P/B | 1.72 | EPS next 5Y | - | ROA | -0.86% | Short Interest | 3.40M | Perf YTD | 0.54% |
| Book/sh | 7.64 | P/C | 3198.99 | EPS past 3/5Y | - | ROE | -0.92% | 52W High | -25.14% ($17.50) | Perf Year | 22.66% |
| Cash/sh | 0 | P/FCF | - | Sales past 3/5Y | - | ROIC | -0.97% | 52W Low | 31.66% ($9.95) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -123.69% | Gross Margin | - | Volatility(W/M) | 9.06% 7.67% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.06 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.2 | EPS Q/Q | -116.28% | Profit Margin | - | RSI (14) | 42.08 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.2 | Sales Q/Q | - | SMA20 | -10.41% ($14.62) | Beta | 0.44 | Target Price | $18 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/11/10 | SMA50 | -11.03% ($14.72) | Rel Volume | 0.68 | Prev Close | $14.01 |
| Employees | 3 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 4.54% ($12.53) | Avg Volume(3M) | 0.87M | Price | $13.1 |
| IPO | 2024/6/12 | Option/Short | No/Yes | Trades | 7663 | Volume | 586,710 | Change | -6.5% |
🧬 Prenom (FRNM) is a diagnostics and research company that uses artificial intelligence and multi-omics analysis to detect early-stage cancer through blood-based testing. Headquartered in California, USA, it is a micro-cap company developing a multi-cancer early detection platform, starting with colorectal cancer.
Over the past 1 year, roughly in the middle
25% below its 1-year high.
Traded less than usual. That is 68% of its average volume.
Next earnings report: November 10
FRNM has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 33.2%.
Tap to view numbers
It ranks #28 of 44 in the industry
Based on market cap of $1B.
FAQ
What kind of company is FRNM?
FRNM belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of FRNM?
The market cap of FRNM is approximately $1.4B, ranking 2,340 within its sector.
What is the 52-week high and low for FRNM?
FRNM has recorded a 52-week high of $17.50 and a low of $9.95.
